Cedars Sinai 1st Annual Cedars-Sinai Fetal Echocardiography Symposium 2026

Description

Include: 35 videos + 35 file sub vtt + 30 pdfs, size: 6.29 GB

Target Audience: cardiologists, electrophysiologists, and cardiac surgeons

1. Overview

The Scripps Health Advancing Cardiovascular Care Emerging Therapies and Strategies 2026 program provides a comprehensive review of the latest clinical breakthroughs in cardiovascular medicine. The course covers advanced management of heart failure, cardiogenic shock, structural interventions, complex cardiomyopathies, and electrophysiology, equipping practitioners with cutting-edge tools to optimize patient outcomes.

Course Date: May 8-9, 2026

This comprehensive continuing medical educational program is designed to equip physicians with the latest knowledge and tools for diagnosing and managing complex cardiovascular conditions. Through a focus on emerging therapies, innovative technologies, and evidence-based strategies, participants will gain practical insights to optimize patient outcomes in a variety of challenging clinical scenarios. Topics will include advancements in heart failure management, mechanical circulatory support, arrhythmia therapies, pulmonary hypertension, cardiogenic shock, and more. Upon completion of this course, participants will be better prepared to integrate cutting-edge therapies and technologies into their practice, improve diagnostic accuracy, and enhance patient-centered care for individuals with cardiovascular diseases.

2. Learning Objectives

1. Analyze the latest evidence and clinical trial data to inform the management of heart failure, pulmonary hypertension, and cardiogenic shock.
2. Identify appropriate patient populations for innovative treatments and integrate them into personalized, multidisciplinary care plans.
3. Evaluate the role of emerging therapies and technologies, including renal artery denervation, Barostim, CCM, and M-TEER, in treating cardiovascular diseases.
4. Develop systematic approaches to diagnosing complex cardiovascular conditions, including amyloidosis, hypertrophic cardiomyopathy (HCM), and cardiorenal syndrome.
5. Optimize the use of advanced mechanical circulatory support devices like VA ECMO, Impella, and subcutaneous ICDs.
6. Improve their understanding of the pathophysiology, clinical manifestations, and management strategies for conditions such as atrial fibrillation, ventricular tachycardia, and shock.

3. Target Audience

Best for cardiologists, electrophysiologists, and cardiac surgeons who want advanced updates on heart failure, structural interventions, and pacing.

4. Topics

1. 01 When to Refer to Advanced Heart Failure VIDEO PDF NOT RELEASE

2. 02 What’s New in HFpEF Trials

3. 03 Finerenone Who, When, and How

4. 04 Beyond GDMT Barostim and CCM

5. 05 Exercise Testing in Heart Failure

6. 06 Cardiorenal Syndrome

7. 07 Panel DiscussionQ&A

8. 08 Role of Renal Artery Denervation

9. 09 Acute PE Shock

10. 10 TAVR in Cardiogenic Shock

11. 11 TTVR vs T-TEER

12. 12 Role of M-TEER in Cardiogenic Shock

13. 13 Panel DiscussionQ&A

14. 14 Stages of Shock

15. 15 Elements of an ECPR Program

16. 16 Troubleshooting MCS at 1 a.m. VIDEO PDF NOT RELEASE

17. 17 Life Hacks for Managing VA ECMO Well

18. 18 Life Hacks for Managing Impella Well VIDEO PDF NOT RELEASE

19. 19 The Cardiogenic Shock Survivor

20. 20 Panel DiscussionQ&A

21. 21 Amyloid Diagnosis and Treatment

22. 22 Therapies in ATTR-CM

23. 23 Therapies in AL-CM

24. 24 HCM Mimickers and Treatment

25. 25 Advanced Imaging in Cardiomyopathies

26. 26 The Amyloid Patient

27. 27 Panel DiscussionQ&A

28. 28 The Different Flavors of Pulmonary Hypertension

29. 29 The Patient Has Pulmonary Hypertension, Now What

30. 30 Pulmonary Hypertension in Congenital Heart Disease

31. 31 CTEPH When to Refer for Surgery

32. 32 Panel DiscussionQ&A

33. 33 Atrial Fibrillation Ablation What’s New

34. 34 Ventricular Tachycardia Ischemic vs. Nonischemic

35. 35 Leadless Pacemakers

36. 36 Subcutaneous ICDs

37. 37 Left Bundle Pacing Are We Ready

38. 38 Panel DiscussionQ&A